Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

BACKGROUND Bone mineral density (BMD)-based guidelines for bone-directed therapy in women with early breast cancer (EBC) appear inadequate for averting fractures, particularly during aromatase inhibitor (AI) therapy. Therefore, an algorithm was developed to better assess risk and direct treatment (Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416). Here, we provide updated guidance on pharmacologic interventions to prevent/treat aromatase inhibitor-associated bone loss (AIBL). DESIGN Systematic literature review identified recent advances in preventing/treating AIBL. Individual agents were assessed based on trial size, design, follow-up, and safety. RESULTS Fracture risk factors in patients with EBC remain unchanged (Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416). The World Health Organization Fracture Risk Assessment Tool algorithm includes fracture risk factors plus BMD but does not adequately address AIBL effects. Several antiresorptives can prevent/treat AIBL. However, concerns regarding compliance and long-term efficacy/safety remain. Overall, evidence is strongest for twice-yearly zoledronic acid (ZOL), and recent advances support additional anticancer benefits from ZOL. CONCLUSIONS All patients initiating AIs need advice regarding exercise, calcium/vitamin D supplements, baseline BMD monitoring (when available), and bone-directed therapy if T-score <-2.0 or at least two fracture risk factors were observed. Patients with T-score > -2.0 and no risk factors should be managed based on BMD loss during years 1-2. Unsatisfactory compliance/decreasing BMD after 12-24 months on oral bisphosphonates should trigger a switch to i.v. bisphosphonate.

[1]  W. Alexander,et al.  American Society of Clinical Oncology , 2020, Definitions.

[2]  L. Lix,et al.  Mortality rates after incident non-traumatic fractures in older men and women , 2011, Osteoporosis International.

[3]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Morgan,et al.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.

[5]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[6]  P. Neven,et al.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  K. Saag,et al.  Health services utilization after fractures: evidence from Medicare. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[8]  J. Manson,et al.  Oral bisphosphonate use and breast cancer incidence in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Carducci,et al.  A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Badamgarav,et al.  Cost of fractures commonly associated with osteoporosis in a managed-care population , 2010, Journal of medical economics.

[11]  M. Moasser,et al.  Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results. , 2010 .

[12]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[13]  U. Dafni,et al.  Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial , 2010, Breast Cancer Research.

[14]  R E Coleman,et al.  The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer , 2010, British Journal of Cancer.

[15]  J. Mackey,et al.  Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Trentham-Dietz,et al.  Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk , 2010, British Journal of Cancer.

[17]  P. Hadji,et al.  Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. , 2010, Critical reviews in oncology/hematology.

[18]  U. Albert,et al.  Assessment of fracture risk in women with breast cancer using current vs emerging guidelines , 2010, British Journal of Cancer.

[19]  G. Rennert,et al.  Use of bisphosphonates and risk of postmenopausal breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Perez,et al.  The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up. , 2009 .

[21]  G. Lenhart,et al.  Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. , 2009, Bone.

[22]  M. Intorcia,et al.  PMS66 GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES , 2009 .

[23]  J. Forbes,et al.  Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  V. Hirsh,et al.  20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma , 2009 .

[25]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  P. Dong,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[27]  E. Perez,et al.  Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC , 2009, Breast Cancer Research and Treatment.

[28]  J. Eisman,et al.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.

[29]  T. Fehm,et al.  Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. , 2009 .

[30]  P. Neven,et al.  The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. , 2009 .

[31]  H. Gothe,et al.  Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis , 2008, Patient preference and adherence.

[32]  F. Schuetz,et al.  Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  R. Chlebowski,et al.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M Kalder,et al.  Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Dodwell,et al.  Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[36]  M. Aapro,et al.  Practical guidance for the management of aromatase inhibitor-associated bone loss. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  S. Perera,et al.  Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Felsenberg,et al.  Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice , 2008, Clinical interventions in aging.

[39]  P. Vestergaard,et al.  Effect of Tamoxifen and Aromatase Inhibitors on the Risk of Fractures in Women with Breast Cancer , 2008, Calcified Tissue International.

[40]  D. Gold,et al.  Compliance and persistence with osteoporosis therapies , 2007, Current rheumatology reports.

[41]  H. Sommer,et al.  [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study]. , 2008, Deutsche medizinische Wochenschrift.

[42]  P. Vestergaard,et al.  Adverse bone effects during pharmacological breast cancer therapy , 2008, Acta oncologica.

[43]  P. Delmas,et al.  Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. , 2007, Bone.

[44]  J. Reginster,et al.  Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club , 2007, Osteoporosis International.

[45]  H. Li,et al.  Meta-analysis of clodronate and breast cancer survival , 2007, British Journal of Cancer.

[46]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[47]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[48]  T. Guise,et al.  Bone loss and fracture risk associated with cancer therapy. , 2006, The oncologist.

[49]  M. Ettinger,et al.  Medication persistence with weekly versus daily doses of orally administered bisphosphonates. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[50]  J. Cuzick,et al.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.

[51]  P. Hadji,et al.  Adhärenz mit täglichen und wöchentlichen oralen Bisphosphonaten in der Osteoporosetherapie , 2006 .

[52]  T. Powles,et al.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.

[53]  J. Reginster.  Adherence and persistence: impact on outcomes and health care resources. , 2006, Bone.

[54]  P. Miller.  Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction , 2005, Current osteoporosis reports.

[55]  N. Sutton,et al.  Osteoporosis and you! , 2005, Medicine and health, Rhode Island.

[56]  C. Blomqvist,et al.  Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients , 2004, Acta oncologica.

[57]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Oberg,et al.  Fracture Risk After Bilateral Oophorectomy in Elderly Women , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  E. Barrett-Connor,et al.  Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. , 2001, JAMA.

[61]  C. Blomqvist,et al.  The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer , 2001, British Journal of Cancer.

[62]  Janet E Brown,et al.  Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer , 2010 .

[63]  S. Steinberg,et al.  Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Thigpen.  Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen , 2010 .

[65]  P. Hadji.  Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. , 2009, Critical reviews in oncology/hematology.

[66]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[67]  G. Hortobagyi,et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  J. Cuzick,et al.  OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) , 2008 .

[69]  A. Howell,et al.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.

[70]  R. Bartl,et al.  [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. , 2006, Deutsche medizinische Wochenschrift.

[71]  P. Delmas,et al.  Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. , 2003, Bone.